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ABSTRACT 
 
BACKGROUND: In secondary hyperparathyroidism (SHPT), enhanced parathyroid 
levels of transforming growth factor-α (TGFα) increase EGF receptor (EGFR) activation 
causing parathyroid hyperplasia, high PTH and also reductions in vitaminD receptor 
(VDR) that limit vitaminD suppression of SHPT. Since anti-EGFR therapy is not an 
option in human SHPT, we evaluated ADAM17 as a therapeutic target to suppress 
parathyroid hyperplasia because ADAM17 is required to release mature TGFα, the 
most potent EGFR-activating ligand.  
METHODS: Computer analysis of the ADAM17 promoter identified TGFα and C/EBPβ 
as potential regulators of the ADAM17 gene. Their regulation of ADAM17 expression, 
TGFα/EGFR-driven growth and parathyroid gland (PTG) enlargement was assessed in 
promoter-reporter assays in A431 cells and corroborated in rat and human SHPT, 
using erlotinib as anti-EGFR therapy to suppress TGFα signals, active vitaminD to 
induce C/EBPβ, or the combination. 
RESULTS: While TGFα induced ADAM17-promoter activity by 2.2-fold exacerbating 
TGFα/EGFR-driven growth, ectopic C/EBPβ expression completely prevented this 
vicious synergy. Accordingly, in advanced human SHPT, parathyroid ADAM17 levels 
correlated directly with TGFα and inversely with C/EBPβ. Furthermore, combined 
erlotinib+calcitriol treatment suppressed TGFα/EGFR-cell growth and PTG 
enlargement more potently than erlotinib in part through calcitriol induction of C/EBPβ 
to inhibit ADAM17 promoter activity, mRNA and protein.  Importantly,  in rat SHPT, the 
correction of vitaminD deficiency effectively reversed the resistance to paricalcitol 
induction of C/EBPβ to suppress ADAM17 expression and PTG enlargement, reducing 
PTH by 50%.  
CONCLUSION: In SHPT, correction of vitaminD and calcitriol deficiency induces 
parathyroid C/EBPβ to efficaciously attenuate the severe ADAM17/TGFα synergy, 
which drives PTG enlargement and high PTH. 
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Short summary:  This work identifies an ADAM17/TGFα synergy that exacerbates 
EGFR-driven parathyroid hyperplasia, and a safe anti-ADAM17 strategy to improve 
treatment of SHPT: TGFα induces ADAM17 gene expression aggravating the vicious 
cycle of ADAM17 release of mature TGFα that enhances TGFα/EGFR-driven 
hyperplasia. Instead, correction of vitaminD and calcitriol deficiency  induceC/EBPβ to 
down-regulate the ADAM17 gene thus attenuatingparathyroid gland enlargement and 
PTH elevations..  
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INTRODUCTION 
 
Secondary hyperparathyroidism (SHPT) is a common and serious complication 
of chronic kidney disease-mineral bone disorders (CKD-MBD)[1, 2].  The degree of 
parathyroid hyperplasia determines both the severity of SHPT and the response to 
therapy[3, 4]: The former by increasing the gland capacity for parathyroid hormone 
(PTH) synthesis and secretion[2], and the latter by reducing parathyroid  levels of the 
vitaminD receptor (VDR), the calcium sensing receptor (CaSR), and the anti-aging 
protein α-klotho, a co-receptor for FGF23[5]. All three receptors mediater the  
suppression of cell growth and serum PTH by vitaminD, calcium, or elevations of 
FGF23 (Refs). Importantly, parathyroid hyperplasia precedes the reductions in 
parathyroid CaSR[6]. Instead, hyperplastic growth and VDR reductions occur 
simultaneously and are caused by EGF receptor (EGFR) activation[7]. Since the 
calcitriol-VDR complex induces CaSR and klotho gene expression[8, 9], the reductions 
in both proteins with parathyroid hyperplasia could be secondary to VDR loss. Thus, 
inhibition of EGFR activation should effectively attenuate the progression of SHPT and 
improve the response to treatment. Fig.1A summarizes the molecular link between 
EGFR activation, hyperplastic growth and VDR loss.  
In rat and human SHPT, the severity of parathyroid EGFR activation is 
determined by CKD-induced increases in parathyroid levels of transforming growth 
factor-α (TGFα, the most potent EGFR-activating ligand)[7, 10, 11], which are 
aggravated by high serum phosphate (P), low calcium (Ca) or vitaminD deficiency[11, 
12]. Enhanced TGFα/EGFR signals induce the synthesis of Activator protein-2 (AP2), a 
transactivator of the TGFα gene[13] and of LIP (for Liver Inhibitory Protein), an 
oncogene and a  transrepressor of the VDR gene[7, 14]   TGFα/EGFR-induction of 
CUG-BP1 phosphorylation and its binding to the third in-frame AUG codon of the single 
C/EBPβ mRNA[15] (Fig. 1B) makes LIP translation prevail over that of the two other 
CAAT-enhancer binding protein-β (C/EBPβ* and C/EBPβ), both potent growth 
suppressors[16] . LIP lacks the transactivation domain but binds C/EBP sequences on 
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DNA with higher affinity than either C/EBPβ molecule[14] LIP acts as an oncogene and 
a VDR gene suppressor  by competing with C/EBPβ homodimers for DNA-binding, or 
by forming LIP/C/EBPβ heterodimers, transcriptionally inactive to induce growth 
arrest[14] and VDR gene expression[7]. In nodular hyperplasia, the worst form of 
human SHPT, the highest TGFα levels concur with the highest LIP content and 
proliferation rates, and with the lowest VDR mRNA and protein[7]. Accordingly, 
inhibition of EGFR activation using erlotinib, a highly specific EGFR tyrosine-kinase 
inhibitor, effectively prevented TGFα induction of: its own gene, LIP levels, proliferation 
rates and  reductions of VDR gene transcription,  in A431 cells[7], in which growth is 
driven  by TGFα and EGFR over-expression[17, 18]and also in established rat SHPT, 
in which only TGFα is enhanced[7]. In these uremic rats, a low calcitriol dose (4 ng 
thrice weekly) which failed to suppress PTH if given during week 4 after 
5/6nephrectomy (NX) due to VDR loss, became effective if preceded by erlotinib 
treatment during week 3[7]. This strategy, however, was insufficient for calcitriol 
suppression of parathyroid hyperplasia[7].  
Since erlotinib treatment is not an option in human SHPT, we searched for a 
target upstream from TGFα activation of the EGFR to prevent PTG growth. We focused 
on ADAM17, the enzyme that cleaves the membrane TGFα precursor releasing  
mature TGFα to the circulation, thus enhancing autocrine, paracrine and endocrine  
TGFα/EGFR-growth[19]. In mouse CKD, systemic inhibition of ADAM17 activity 
attenuated angiotensin II-induced TGFα/EGFR-driven proteinuria and damage to the 
renal parenchyma as effectively as global TGFα gene deletion or renal-specific EGFR 
inactivation[20]. However, current ADAM17 inhibitors are highly toxic to be used 
therapeutically in SHPT[21, 22]. To overcome this limitation, a computer analysis of the 
ADAM17 promoter searched for targetable regulators of ADAM17 gene expression. 
The identification of 13 putative C/EBP and 4 AP2 binding sites suggested that 
enhanced parathyroid TGFα/EGFR induction of LIP[7]and AP2[13] could increase 
ADAM17 gene expression further aggravating growth rates and VDR loss. Importantly, 
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it also revealed a potentially safe anti-ADAM17 strategy: calcitriol (1,25D) induction of 
parathyroid C/EBPβ, as demonstrated in other cell types[23-26].  Therefore, herein, in 
vivo, ex vivo and in vitro protocols tested the hypothesis that simultaneous treatment 
with erlotinib and calcitriol should enhance erlotinib potency to suppress parathyroid 
growth through an effective induction of C/EBPβ to inhibit ADAM17 gene expression.  
In addition, because 25-hydroxyvitaminD (25D) enhances calcitriol/VDR-
antiproliferative actions in various cancer cell types[27], we examined whether this 
25D/calcitriol synergy could  compensate for parathyroid VDR loss and induce C/EBPβ 
repression of  the ADAM17-gene  and PTG enlargement without erlotinib. To evaluate 
the contribution of 25D conversion to calcitriol to the 25D+active vitaminD 
synergy,calcitriol treatment had to be substituted by its analog, paricalcitol[28]. 
 
METHODS 
Cell Culture and Proliferation Assays: The human epidermoid carcinoma cell 
line A431 (ATCC) was grown in 10%FBS DMEM (Invitrogen) at 37°C in 5%CO2. Either 
106 (10-cm plate) or 104 cells (96-well plates) were synchronized at G0 using serum-
free DMEM for 8h, and treated with erlotinib (in DMSO), 1,25-dihydroxyvitaminD (in 
ethanol) or the combination in 2%FBS DMEM for 60h followed by 1%BSA DMEM up to 
84h.   
The colorimetric 3-(4,5 dimethylthiazol-2-yl)2-5-diphenyl tetrasodium bromide 
assay kit (Chemicon International) measured A431  proliferation.  
RT-PCR for human ADAM17: Total RNA was extracted using RNA-Bee (TEL-
TEST) and quantified by UV-VIS spectrophotometer (Nanodrop Technologies). First-
strand cDNA was obtained from 2μg RNA using Omniscript Reverse Transcription 
reagents (Qiagen). Cycling conditions for RT-PCR for ADAM17 and cyclophilinB were: 
5’ at 94°C, 40 or 24 cycles, respectively, of 30” at 94°C, 30” at 57°C or 54°C 
respectively, 45” at 72°C, with final 5’extension at 72°C. RT-PCR products were 
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electrophoresed in 1% agarose gels, visualized using a transilluminator (Sigma 
Chemical T1202) and quantified with ImageJ. Primer sequences were: ADAM17: 
forward:5-TCATTGACCACGTGAGCATC-3; reverse:5-
TCGTCCATATGTGAGTCTGTGC-3; CycB: forward:5-GTGATCTTTGGTCTCTTCGG-
3; reverse:5-CGATGATCACATCCTTCAGG-3.   
Plasmids:  
ADAM17-luciferase reporter: The human ADAM17 promoter fragment [-2305 to 
-1 before ATG] containing 13 C/EBP and 4 AP2 putative binding sites, was PCR 
amplified with forward primer:5-GATAAACTAATTAATCTATCC-3 and reverse primer:5-
GAGTCGGTAGCGGGGCCGGGAAC-3, subcloned into T-vector (pBluescript II), 
sequenced, and inserted into pGL2-Basic vector (between Kpn I and Hind III). 
 Expression vector exclusive for human C/EBPβ: The LIP’s ATG (Met) was 
replaced by TCC (Ser) to impede the initiation of LIP translation (Fig. 1). The 5’-
fragment of the human mutant C/EBPβ was PCR amplified, forward primer:5-
TATGGAAGTGGCCAACTTCTAC-3 and reverse primer:5-
AGGATCCTGCGCCGCCGCCCGGCGC-3; and the human mutant C/EBPβ 3’-
fragment with forward primer:5-AGGATCCGCGGCGGGCTTCCCGTACGCG-3 and 
reverse primer:5-ATCTAGACTAGCAGTGGCCGGAGGAGG-3. PCR fragments were 
cloned into T-vector (pBluescript II) and sequenced. 5’- and 3’-fragments were 
assembled with BamHI, and subcloned into expression vector pcDNA3.  
  Promoter-reporter assays: 1μg of the human ADAM17 luciferase reporter and 
0.1μg of the β-galactosidase expression plasmid[7] with or without 0.1μg of the 
C/EBPβ expression vector were transiently transfected (Myrus Transfection reagents, 
using 4μl/1μg of DNA following manufacturer's protocols) into A431 cells, plated at a 
concentration of 3×105 cells/ml media/well. pGEM DNA was added when required to 
maintain the total amount of transfected DNA constant. Upon an overnight incubation, 
cells were treated with vehicle or TGFα 8nM for 24h, then lysed, and luciferase and β-
8 
 
galactosidase activities measured using Luciferase reporter system (Promega) and 
Galacto-Light (Applied Biosystems).  
 Protocols for rat SHPT: Female Sprague-Dawley rats (200-225 g) underwent 
5/6NX as in[7] and were fed a high P diet for 4 weeks (0.9% P, 0.6% Ca; Dyets). 
Protocol 1: Rats received from week 2 to 4, either vehicle (200μl of DMSO), erlotinib 
(6mg/kgbw, daily, in 100μl propylene glycol as in[7]; Genentech), 1,25-
dihydroxyvitaminD (4ng thrice weekly in 200µl of propylene-glycol:PBS 1:1), or the 
combination.  
Protocol 2; One week after 5/6NX, rats received either vehicle, 25-
hydroxyvitaminD (800ng weekly) to correct vitamin D deficiency; paricalcitol (16ng, 
equivalent to 4 ng calcitriol in PTH suppression[28], thrice weekly) or the combination, 
for 3 weeks.  A group of 5/6NX rats were fed a low P diet (0.2%P; 0.5%Ca) throughout 
the study.  
At sacrifice, blood was drawn for analytical determinations. PTG were removed 
and weighed (Cahn Instruments). For immunohistochemistry, glands were fixed in 
formalin and paraffin included. Plasma P, creatinine, ionized Ca, and intact PTH levels 
were measured as described[7]. All animal protocols were approved by the Animal 
Study Committee at Washington University.  
Human PTG: Cryopreserved 1-2 mm3 sections of 32 human PTG were obtained 
at parathyroidectomy from advanced CKD patients (Vall d'Hebron Hospital, Barcelona, 
Spain, kindly provided by Dr. Galicia)  
Immunohistochemistry: Antigen retrieval, quenching and blocking in rat PTG 
was performed as described[7]. Primary antibodies against ADAM17 (Genetex, 1:50), 
C/EBPβ (Biolegend, 1:50, directed to an epitope in the N-terminal domain absent in 
LIP), and PCNA (Biolegend 1:500) were added overnight at 4ºC, followed by 
biotinylated secondary antibody and streptavidin–horseradish peroxidase conjugate. 
Immune complexes were visualized with aminoethyl carbazole substrate-chromagen 
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(Histostain-plus, Invitrogen). For negative controls, one section was left without primary 
antibody. ADAM17, C/EBPβ and PCNA were quantified in at least three sections per 
gland, as in[12]. A semi-quantification scoring:1+(low intensity);4+(high intensity) 
evaluated PTGs from the 25D/paricalcitol protocol.  
For human PTG, upon an overnight exposure with the primary antibody: 
ADAM17 (Abcam 1:200); TGFα (GF10, Calbiochem 1:20); VDR (Millipore 1:200); 
C/EBPβ (Biolegend 1:100), sections were washed,  the appropriate Alexa-fluor 
secondary antibodies and Hoechst added for 1h, and quantified with  ImageJ.  
Western Blots: A431 cells: whole cell and nuclear extracts were obtained using 
1%RIPA Buffer/protease inhibitor cocktail (Roche), or Nuclear Extract Kit (Active Motif), 
respectively. Protein concentration was quantified by Bio-Rad Protein Assay (Bio-Rad 
Laboratories). Protein was resolved by either 10% or 12%SDS-PAGE, and 
electroblotted onto PVDF (Immobilon-P transfer membrane; Millipore) membranes. 
After probing overnight at 4°C with primary antibodies (Total C/EBPβ [Santa Cruz 
1:1000, directed to an epitope in the C-terminal domain common to the 3 isoforms], 
ADAM17 [Genetex 1:1000]) blots were visualized by enhanced chemiluminescence 
(SuperSignal West Pico; Pierce), and quantified with ImageJ.  
Statistical Analyses: ANOVA assessed statistical differences among all 
experimental groups, with Bonferroni tests (or unpaired t test analysis when indicated) 
to compare selected pair of groups.  
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RESULTS  
Calcitriol/erlotinib synergy to suppress PTG growth involves induction of 
C/EBPβ 
Figure 2A and table 1 show that, in rat established SHPT, treatment from week 
2 to 4 after 5/6NX with erlotinib and calcitriol (at a selected dose, ineffective to 
suppress PTG enlargement to mimic calcitriol resistance due to VDR loss), had a 
higher potency than erlotinib alone in inhibiting proliferation, as measured by 
parathyroid PCNA and PTG weight/bw, and in enhancing PTH suppression by calcitriol 
from 16 to 34.5%. This higher potency was unrelated to differences in serum 
creatinine, Ca and P levels, and associated directly with the doubling of parathyroid 
C/EBPβ protein (p<0.05) and with marked reductions in parathyroid ADAM17 
immunostaining (Fig. 2B). Neither monotherapy enhanced parathyroid C/EBPβ above 
the levels in untreated controls. To overcome the limitation in estimating  parathyroid 
C/EBPβ/LIP ratio immunohistochemically, as  LIP antibodies recognize C/EBPβ (See 
Fig. 1B), the contribution of increases in C/EBPβ/LIP ratio to suppress ADAM17 gene 
expression was examined in A431 cells, upon reproducing the down-regulation of 
TGFα/EGFR-growth by erlotinib and calcitriol observed in rat SHPT. 
Calcitriol/erlotinib synergy to inhibit TGFα/EGFR-growth involves the 
induction of C/EBPβ:LIP ratio to suppress ADAM17 gene expression  
The combination of erlotinib (0.25 µM)+calcitriol (10-7M, a dose ineffective to 
suppress A431 growth), inhibited proliferation more potently than erlotinib alone (Fig. 
3A), in part through a higher suppression of ADAM17-promoter activity (Fig. 3B). Only 
erlotinib+calcitriol treatment, which increased nuclear C/EBPβ:LIP ratio by 9-fold (Fig. 
3C),  reduced ADAM17 mRNA and protein expression (Fig. 3D and 3E).  
ADAM17 gene expression is induced by TGFα and suppressed by C/EBPβ  
  Treatment of A431 cells with 8nM TGFα for 48h caused a 2.2-fold increase in 
ADAM17-promoter activity (Fig. 4A), which was reduced by 43% through ectopic 
expression of C/EBPβ.  
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Accordingly, immunofluorescent analysis of human hyperplastic glands (Fig. 
4B,Top) demonstrated that the highest ADAM17 levels co-localized with the highest 
cell membrane TGFα expression, both whole and ADAM17-cleaved TGFα precursors, 
(Left). Instead, the lowest ADAM17 and TGFα expression concurred with the highest 
nuclear C/EBPβ and VDR content (Right). Furthermore, Fig. 4B, (bottom panels) 
shows that parathyroid ADAM17 strongly correlated directly with TGFα (r2=0.571, 
p<0.007) and inversely with C/EBPβ (r2=0.572, p<0.03). 
Next, we examined whether, in rat SHPT, 25D enhancement of calcitriol/VDR 
antiproliferative actions sufficed to induce parathyroid C/EBPβ to suppress ADAM17 
and PTG enlargement despite VDR loss.  To measure whether 25D conversion to 
calcitriol contributes to the 25D/calcitriol synergy, paricalcitol replaced calcitriol 
treatment.[28]  
25-hydroxyvitaminD+paricalcitol suppresses parathyroid ADAM17 and 
gland enlargement in rat SHPT as effectively as erlotinib+calcitriol 
Fig. 5 shows that despite similar serum creatinine, P, total and ionized Ca 
among all experimental groups (Table 2), and also despite the normalization of serum 
25D  in rats receiving 25D, only rats receiving the 25D+paricalcitol combination from 
week 1 after 5/6NX could prevent further PTG enlargement reducing PTH by 50%. This 
reduction in PTG enlargement associated to a marked reduction (7.5-fold) of 
parathyroid ADAM17 protein and a 2-fold increase in parathyroid C/EBPβ over 
untreated controls, a potency similar to that of dietary P restriction (1.95-fold p<0.01).  
Serum calcitriol was similar in rats receiving combined 25D+paricalcitol compared to 
those receiving paricalcitol alone.  Thus, normalization of serum 25D sufficed to 
reverse the resistance to a low dose of paricalcitol in doubling C/EBPβ and in 
suppressing ADAM17 protein and PTG enlargement.  
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DISCUSSION  
This work presents ADAM17 as a critical target upstream from EGFR activation 
to improve current vitaminD strategies to treat SHPT (Fig. 6), as it identified: 1) TGFα 
induction of ADAM17 promoter activity as the initiator of a powerful ADAM17-
dependent autocrine loop that agravates the already enhanced TGFα/EGFR-growth 
signals; 2) C/EBPβ trans-repression of the ADAM17 gene as a mechanism by which 
active vitaminD therapy enhances the efficacy of anti-EGFR therapy; 3) A 
25D/paricalcitol synergy that  induces parathyroid C/EBPβ and attenuates the 
increases in parathyroid ADAM17 causing PTG enlargement, as efficacious as 
combined erlotinib-calcitriol treatment.   
TGFα upregulation of ADAM17 gene expression provides a previously 
unrecognized pathogenic mechanism that aggravates the severe growth patterns 
associated with ADAM17/TGFα co-expression. Specifically, ADAM17 activity is 
essential to release mature TGFα, the stronger EGFR activator. In fact the ADAM17 
null mouse dies perinatally due to severe developmental defects in the morphogenesis 
of epithelial organs including the PTG[29]. Undoubtedly, in human SHPT, ADAM17 
activity is mandatory for the strong association between TGFα content and proliferation 
rates[7]. Furthermore, TGFα activation of the EGFR also increases ADAM17 
stability[30],  the phosphorylation required for ADAM17 translocation to the plasma 
membrane for activity[31, 32] and causes a 2.2-fold increase in ADAM17 gene 
expression. Clearly,  TGFα induction of ADAM17 promoter activity and post-
transcriptional modifications generate an ADAM17/TGFα synergy that may contribute 
to nodule formation, as over-expression of LIP in normal mouse mammary glands is 
sufficient to induce hyperproliferation and tumorigenesis[33]. The presence of several 
AP2 and C/EBP putative binding sites in the human ADAM17 promoter suggested that 
anti-EGFR therapy should prevent both TGFα induction of parathyroid AP2[13] and 
LIP[7] and consequently, ADAM17 gene upregulation. Since LIP antagonizes C/EBPβ 
actions, we examined whether part of C/EBPβ antiproliferative actions involved 
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ADAM17 gene suppression. We found that, in A431 cells, in which not only TGFα but 
also EGFR is overexpressed[17], ectopic C/EBPβ expression prevented  the doubling 
of ADAM17 promoter activity induced by TGFα and reduced ADAM17 gene expression 
by 43%.  This finding suggested that calcitriol induction of C/EBPβ[23-26] could provide  
asafe anti-ADAM17 strategy to break the deleterious ADAM17/TGFα synergy upstream 
from EGFR activation. The demonstration in hyperplastic PTG from patients with 
advanced CKD, that parathyroid ADAM17 content correlated directly with TGFα and 
inversely with C/EBPβ content led us to evaluate, in rat CKD, the efficacy of 
simultaneous anti-EGFR and anti-ADAM17 treatment in attenuating PTG hyperplasia. 
In established rat SHPT, in which only TGFα, but not EGFR, is overexpressed[7], 
simultaneous treatment with erlotinib, a suppressor of LIP synthesis, and calcitriol, an 
inducer of C/EBPβ expression, from week 2 to week 4 after 5/6NX, is more effective 
than erlotinib alone in attenuating further increases in PTG enlargement and serum 
PTH, despite similar serum levels of creatinine, Ca and P. The higher suppression of 
parathyroid cell growth by the erlotinib/calcitriol combination associated directly with the 
doubling of parathyroid C/EBPβ content, and with marked reductions in ADAM17 
protein, supporting but not proving, the transcriptional control of the ADAM17 gene by 
increases in parathyroid C/EBPβ.  
 Next, studies in A431 cells conclusively demonstrated that inhibition of the 
ADAM17 gene mediated, at least in part, the higher potency of the erlotinib/calcitriol 
combination over that of erlotinib alone to inhibit TGFα/EGFR-driven growth. This 
improved outcome associated with a 9-fold elevation in C/EBPβ:LIP ratio, which 
resulted in significantly reduced ADAM17 mRNA and protein expression. 
Since anti-EGFR is not a choice in human SHPT, and current ADAM17 
inhibitors are highly toxic [21, 22], we also examined in rat SHPT whether 25D 
enhancement of calcitriol/VDR antiproliferative actions[27] could safely substitute for 
erlotinib reversal of the resistance to active vitaminD suppression of PTG growth 
caused by VDR loss. Intraperitoneal administration of 25D to normalize serum vitaminD 
14 
 
levels  starting one week after 5/6NX,  , effectively reversed the resistance to 16ng of 
paricalcitol in inducing C/EBPβ and suppressing ADAM17 expression and PTG 
enlargement, with a potency similar to either combined erlotinib+calcitriol treatment or 
P restriction,  resulting in a 50% PTH reduction.  
The mild elevations in serum 1,25D in rats treated with combined 
25D+paricalcitol compared to those receiving paricalcitol alone suggested that local 
conversion of 25D to calcitriol could partially account for the synergy. However, direct 
activation of VDR antiproliferative actions by 25D should not be ruled out, as 25D can 
directly activate the VDR and also synergize with calcitriol in cells from the 1α-
hydroxylase null mouse[34] or upon specific inhibition of 25D conversion to 
calcitriol[35]. 
This 25D/active vitaminD synergy is translationally relevant: Fist, it unraveled a 
novel mechanism supporting the recommendation by the KDIGO guidelines to correct 
vitaminD deficiency to improve outcomes in SHPT at all CKD stages. Secondly, it 
provided a potentially safe alternative for patients whose high serum calcium and 
phosphate levels preclude escalating the dose of paricalcitol to suppress PTH[28, 36, 
37]. Thirdly, it demonstrated that the correction of vitaminD deficiency in CKD patients 
that are not receiving active vitaminD therapy may not suffice to reach sufficient 25D 
levels within parathyroid cells to compensate for VDR reductions and effectively 
attenuate ADAM17/TGFα-driven hyperplasia. Indeed, in CKD stage 3-4, vitaminD 
supplementation that normalized serum 25D and 1,25D levels, was ineffective in 
suppressing PTH[38-41]. Mechanistically, in hemodialysis patients, CKD-induced 
reductions in 25D uptake by circulating monocytes is corrected by calcitriol[42]. Similar 
defective 25D uptake  may occur in the PTG due to  CKD-induced decreases in the 
endocytic receptor megalin[43], highly expressed in the parathyroids[44]. Since active 
vitaminD induces megalin[45], combined 25D+active vitaminD could enhance both 
parathyroid 25D uptake and  25D/active vitaminD synergy for ADAM17suppression. A 
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similar synergy for 25D uptake by proximal tubular cells from the glomerularultrafiltrate 
should help maintain serum 25D levels[46].  
An important consideration before the clinical application of this 25D+active 
vitaminD synergy to treat human SHPT is that in these pre-clinical studies, nutritional 
and active vitaminD were administered intraperitoneally. The oral formulations more 
commonly used in CKD patients could increase the risk for hypercalcemic and 
hyperphosphatemic epidoses as a result of synergic 25D/active vitaminD interactions 
enhancing intestinal calcium and phosphate absorption. Therefore, the safe transfer of  
this synergy to the bed site requires the identification of non-invasive markers of 
parathyroid ADAM17 inhibition.. Measurements of reductions in circulating mature 
TGFα levels in response to vitaminD therapy may l not be accurate, as they reflect both 
parathyroid and renal ADAM17 activity in CKD[20, 47]. Importantly, the results from the 
25D+active vitaminD protocols also suggested that simple measurements of the ability 
of vitaminD supplementation alone or in combination with low doses of active vitaminD 
(either calcitriol or paricalcitol), to effectively normalize serum 25D above 30 ng/ml and 
reduce PTH by 50%,  could help personalize nutritional and active vitamin D 
interventions to reach the appropriate parathyroid 25D/active vitamin D synergy for 
ADAM17 inhibition. This is a mandatory first step prior to the much needed prospective, 
well powered clinical studies.  
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Table 1:  Serum chemistry, body weight and changes in parathyroid features with 
treatment. 
  
Vehicle  
(n=7) 
erlotinib 
 (n=8) 
1,25D  
(n=7) erlotinib+1,25D (n=6) 
ICa (mg/dl) 4.56± 0.08 4.68± 0.12 4.71± 0.07 4.76± 0.14 
Creatinine (mg/dl) 1.38± 0.12 1.20± 0.12 1.20± 0.08 1.14± 0.10 
Total Ca (mg/dl) 9.95± 0.16 10.32± 0.20 10.6± 0.10 10.43± 0.23 
P (mg/dl) 7.74± 0.63 8.06± 0.64 7.16± 0.48 7.66± 0.63 
PTH (pg/ml) 427.6± 120.0 414.9± 116.0 359.6± 62.5 280.0± 82.2 
Body weight (g) 271.0± 4.8 272.4± 3.7 277.1± 4.7 272.0± 5.4 
PCNA 
(+Nuclei/Area) 
0.42± 0.08 
(N=12) 
0.21± 0.03 
(N=14) * 
0.28± 0.07 
(N=9) 
0.14± 0.05  
(N=8) *** 
CEBPβ (IOD/Area) 36.6± 5.3 37.7± 6.3 39.4± 5.5 56.6± 4.7* 
 
Values indicate Mean±SEM in 5/6NX rats fed a high P (HP) diet and treated with 
vehicle, erlotinib (6 mg/kg bw, daily, ip in 100μl DMSO), calcitriol (1,25D, 4 ng thrice 
weekly in 200 μl of propyleneglycol:PBS 1:1), or the combination, from week 2 to week 
4 after 5/6NX. Abreviations: ICa=ionized calcium; PTH=parathyroid hormone; 
PCNA=Proliferating Cell Nuclear Antigen where n=number of rats and N=number of 
parathyroid glands examined. *, ** and *** indicate p<0.05; p<0.01 and p<0.001 vs. HP. 
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Table 2:  Serum chemistries and parathyroid C/EBPβ content with treatment. 
 Sham LP HP HP+25D HP+Pari HP+25D+ Pari 
Creatinine 
(mg/dl) 
0.73±0.05 1.65±0.26 1.38±0.11 1.53±0.14 1.52±0.10 1.46±0.17 
Total Ca 
(mg/dl) 
9.86±0.11 10.56±0.22 9.82±0.15 9.68±0.40 9.70±0.26 9.63±0.26 
ICa 
(mg/dl) 
4.85±0.05 4.84±0.07 4.47±0.13 4.39±0.17 4.35±0.14 4.42±0.17 
P 
(mg/dl) 
5.14±0.27 5.13±0.39 8.12±0.92 7.78±1.25 9.03±0.68 8.08±1.00 
PTH 
(pg/ml) 
91.5±34.3 272.3±58.0 3,555.7±776.4 3,562±151 3098.2±437 1,550±819 
25D 
(ng/ml) 
32.2±2.2 22.1±6.8 16.6±4.0 27.4±7.4 17.9±3.3 33.1±9.8 
1,25D 
(pg/ml) 
125.3±17.8 83.6±29.7 94.3±27.9 89.7±16.7 29.7±7.6 37.8±3.3 
C/EBPβ 
(Score) 
--- 3.25±0.25 
(4) 
1.67±0.33 ** 
(3) 
2.0±1.0 
(3) 
2.0±0.58 
(4) 
3.0±0.41 ^ 
(4) 
 
Values indicate Mean±SEM in at least 5 5/6NX rats fed either a low P (LP) or  a high P 
(HP) diet and treated with vehicle (HP), 25D (800ng once weekly, ip in 200 μl of 
propyleneglycol:PBS 1:1); paricalcitol (Pari, 16 ng thrice weekly in 200 μl of 
propyleneglycol:PBS 1:1), or the combination, from week 1 to week 4 after 5/6NX. 
Abreviations: ICa=ionized calcium; PTH=parathyroid hormone; 25D=25-hydroxyvitamin 
D; 1,25D= 1,25-dihydroxyvitamin D; C/EBPβ= parathyroid levels of C/EBPβ protein, 
where (number) indicates the number of parathyroid glands examined. ** indicates 
p<0.01 vs. LP and ^ indicates p<0.06 vs. HP. 
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LEGENDS TO FIGURES 
Figure 1: Pathogenesis of severe EGFR-driven growth and VDR loss. A.  
TGFα/EGFR induction of AP2 and LIP synthesis exacerbate growth and VDR loss 
through TGFα gene upregulation and VDR gene downregulation. B. Structure of the 
C/EBPβ mRNA and protein isoforms: A single C/EBPβ mRNA encodes (darker lane) 
for 3 distinct proteins C/EBPβ* (LAP1), C/EBPβ (LAP2) and dominant negative C/EBPβ 
(LIP) through their translation initiation (AUG) from 3 distinct in-frame translation sites. 
TGFα induces LIP translation through activation and binding of CUG-BP1 to the 3rd in 
frame AUG. The protein diagram indicates transactivation, DNA binding and leucine 
zipper regions.   
 
Figure 2: The higher potency of the erlotinib/calcitriol combination compared to 
erlotinib alone to suppress PTG enlargement in rat SHPT associates with marked 
reductions in parathyroid ADAM17.   
A. Scheme of the experimental protocol. B. Top: Representative immunostaining for 
parathyroid ADAM17 expression. Magnification X200; Bottom: Bars and error bars 
represent Mean±SEM of parathyroid gland (PTG) weight/body weight from 5/6NX rats 
fed a high P diet (HP) and receiving vehicle (HP), or calcitriol (HP+1,25D); erlotinib 
(HP+ertotinib), or the combination(HP+erlotinib+1,25D), at the concentrations specified 
in Methods. * and ** indicate p<0.05 or p<0.01 vs. HP. 
 
Figure 3: TGFα and vitamin D regulation of ADAM17 expression.  
A. Growth rates (MTT assay) of A431 cells treated for 84 h with vehicle (Control), 
erlotinib 0.25μM, calcitriol (1,25D) 100nM or the combination (erlotinib+1,25D). Bars 
and error bars represent the Mean±SEM from 3 independent experiments. ** and *** 
indicate p<0.01 and p<0.001 vs. controls; ^ indicates p< 0.05 vs. erlotinib. 
B. Promoter/reporter assay of luciferase activity driven by the human ADAM17 
promoter, corrected by β-galactosidase (βgal), in A431 cells treated as in A. Bars and 
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error bars represent the Mean±SEM of at least triplicate determinations per condition 
from 2 independent experiments. ** and ^ indicate p<0.01 vs. Control and p<0.05 vs. 
erlotinib  
C: Top: Representative western blot analysis of nuclear LAP1/2 and LIP expression in 
A431 cells treated as in A; Bottom: Nuclear C/EBPβ (LAP1/2): LIP ratios, in A431 cells 
treated as in A. Bars and error bars represent the Mean±SEM from at least 4 
independent experiments; ** indicates p<0.01 vs. controls. 
D and E: Top panels: Representative RT-PCR for ADAM17 (D) and the loading control 
Cyclophillin B (CypB) and Western blot analysis (E) of pro-ADAM17 and active 
ADAM17 protein expression and the loading control GAPDH in A431 cells treated as in 
A.  Bottom panels: Densitometric analysis of ADAM17 mRNA expression corrected for 
the housekeeping gene CypB(D) and of ADAM17 protein expression corrected for 
GAPDH as the loading control (E) in A431 cells treated as in A. Bars and error bars 
represent the Mean±SEM from at least 2 independent experiments. * indicates p<0.05 
vs. controls  
 
Figure 4: Increased parathyroid TGFα and ADAM17 concur with low VDR and 
C/EBPβ in human hyperplastic glands from SHPT.  A. Promoter/reporter assay of 
human ADAM17 promoter activity, corrected by βgal, in A431 cells treated with vehicle 
(Control) or TGFα 8 nM (TGFα), and transfected with empty vector (Control+Empty 
vector) or with a C/EBPβ expression vector.  Bars and error bars represent the 
Mean±SEM from 6 and 2 independent experiments with triplicate determinations each, 
for TGFα treatment or upon ectopic C/EBPβ expression, respectively. Results are 
expressed as % of respective controls. 
B. Top Panels: Representative immunofluorescence of ADAM17, TGFα, VDR 
and C/EBPβ expression and co-localization in two distinct areas from a single patient. 
Merge 1: Hoechst (Blue), ADAM17 (green); TGFα (red); Merge 2: Hoechst (Blue); VDR 
(gray); C/EBPβ (red); ADAM17 (green). Magnification 40X.  
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Bottom Panel: (left): Correlation between parathyroid ADAM17 and TGFα in 11 
nodules from the parathyroid glands from 4 patients: r2=0.571, p=0.007. Bottom panel 
(right): Correlation between parathyroid ADAM17 and C/EBPβ in 8 nodules from the 
parathyroid glands from 6 patients: r2=0.572, p=0.03.  
 
Figure 5: 25-hydroxxyvitaminD enhances paricalcitol efficacy to suppress 
parathyroid ADAM17 and gland enlargement in rat SHPT  
 A. Scheme of the experimental protocol in rats fed either a high P (HP) or a low 
P diet (LP) throughout the 4 weeks after 5/6NX or sham operation, and treated with 
vehicle,  25-hydroxyvitaminD (HP+25D); Paricalcitol (HP+Pari) or the combination 
(HP+Pari+25D) at the concentrations specified in Methods, starting 1 week after NX;  
B. Bars and error bars represent Mean±SEM of parathyroid gland (PTG) 
weight/body weight in rats treated as in A; 
 C. Top: Representative immunostaing for parathyroid ADAM17 expression; 
Bottom: Bars and error bars represent Mean±SEM of parathyroid ADAM17 expression 
estimated by the quantification of ADAM17 immunostaining per area (IOD/Area), 
respectively, from sham operated (Sham) or 5/6NX rats treated as indicated. * and *** 
indicate p<0.05 or p<0.001, respectively vs. LP; # and ## indicate p<0.05 or p<0.01, 
respectively vs. HP.  
 
Figure 6: Molecular bases for ADAM17/TGFα induction of severe 
parathyroid hyperplasia in SHPT and its suppression by vitamin D. TGFα 
induction of ADAM17 gene transcription reinforces the vicious autocrine loop of 
enhanced ADAM17 release of TGFα and TGFα activation of the EGFR to induce LIP-
driven growth exacerbation and ADAM17 gene transcription in A431 cells and in rat 
and human SH. 1,25-dihydroxyvitaminD efficacy to enhance C/EBPβ synthesis 
contributes to inhibit ADAM17 gene expression. 25-hydroxyvitaminD enhances 1,25-
dihydroxyvitaminD actions induction of C/EBPβ to suppress ADAM17 gene expression.  
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